STAT3 can serve as a hit in the process of malignant transformation of primary cells

Cell Death and Differentiation

Volumn 19, Issue 8, 2012, Pages 1390-1397

  Demaria, M ^a,b   Misale, S ^a,d   Giorgi, C ^c   Miano, V ^a   Camporeale, A ^a   Campisi, J ^b   Pinton, P ^c   Poli, V ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c UNIVERSITY OF FERRARA   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

3T3 MEFs; aerobic glycolysis; apoptosis; HIF 1 ; STAT3; tumorigenesis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; STAT3 PROTEIN;

AEROBIC METABOLISM; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; GLYCOLYSIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

MUS;

EID: 84863723266     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.20     Document Type: Article

References (38)

1. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-6626. (Pubitemid 32197700)
2. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007; 104: 7391-7396. (Pubitemid 47185916)
3. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059-20063. (Pubitemid 47099977)
4. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-83.
5. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-2558. (Pubitemid 28183425)
6. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-8023. (Pubitemid 39468859)
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. (Pubitemid 29380565)
8. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004; 101: 10602-10607. (Pubitemid 38955788)
9. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011; 208: 1359-1366.
10. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
11. Yu H, Pardoll DM, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
12. Pensa S, Regis G, Boselli D, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: two sides of the same coin? In: Stephanou A (eds). JAK-STAT Pathway in Disease. Landes Bioscience: Austin, 2009, pp 100-121.
13. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010; 70: 2558-2567.
14. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010; 2: 823-842.
15. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324: 1713-1716.
16. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009; 323: 793-797.
17. Demaria M, Poli V. From the nucleus to the mitochondria and back: the odyssey of a multitask STAT3. Cell Cycle 2011; 10: 3221-3222.
18. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-634.
19. Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402. (Pubitemid 351681994)
20. Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 2006; 118: 2609-2616.
21. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13: 493-501. (Pubitemid 37266952)
22. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 2009; 119: 1093-1108.
23. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-270.
24. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
25. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963; 17: 299-313.
26. Krontiris TG, Cooper GM. Transforming activity of human tumor DNAs. Proc Natl Acad Sci USA 1981; 78: 1181-1184. (Pubitemid 11102184)
27. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120. (Pubitemid 44040989)
28. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653. (Pubitemid 43902663)
29. Chan KS, Sano S, Kataoka K, Abel E, Carbajal S, Beltran L et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 2008; 27: 1087-1094. (Pubitemid 351253189)
30. Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007; 67: 8494-8503. (Pubitemid 47437423)
31. Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K. Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer 2011; 105: 407-412.
32. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011; 19: 429-431.
33. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999; 189: 63-73. (Pubitemid 29047027)
34. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. (Pubitemid 37328811)
35. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002; 13: 29-37. (Pubitemid 35418312)
36. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-2433. (Pubitemid 28371361)
37. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602. (Pubitemid 27152402)
38. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006; 116: 3171-3182. (Pubitemid 44878631)